{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:06:25Z","timestamp":1775027185038,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10557-018-6794-x","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T22:10:47Z","timestamp":1527027047000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data"],"prefix":"10.1007","volume":"32","author":[{"given":"Richard","family":"Ofori-Asenso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"6794_CR1","doi-asserted-by":"crossref","unstructured":"Ofori-Asenso R, Zomer E, Curtis A, Zoungas S, Gambhir M. Measures of population ageing in Australia from 1950 to 2050. J Popul Ageing. 2017:1\u201319.","DOI":"10.1007\/s12062-017-9203-5"},{"key":"6794_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14336\/AD.2014.1210","volume":"6","author":"K Jin","year":"2015","unstructured":"Jin K, Simpkins JW, Ji X, Leis M, Stambler I. The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. Aging Dis. 2015;6:1\u20135.","journal-title":"Aging Dis"},{"key":"6794_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/2047487313480435","volume":"20","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20:641\u201357.","journal-title":"Eur J Prev Cardiol"},{"key":"6794_CR4","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532\u201361.","journal-title":"Lancet"},{"key":"6794_CR5","doi-asserted-by":"publisher","first-page":"f6123","DOI":"10.1136\/bmj.f6123","volume":"347","author":"JD Abramson","year":"2013","unstructured":"Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.","journal-title":"BMJ"},{"key":"6794_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/jgs.12788_1","volume":"62","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Intwala S, Katz D. Statins in very elderly adults (debate). J Am Geriatr Soc. 2014;62:943\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"6794_CR7","first-page":"431","volume":"12","author":"J Pedro-Botet","year":"2015","unstructured":"Pedro-Botet J, Climent E, Chillaron JJ, Toro R, Benaiges D, Flores-Le Roux JA. Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol. 2015;12:431\u20138.","journal-title":"J Geriatr Cardiol"},{"key":"6794_CR8","doi-asserted-by":"publisher","first-page":"i3283","DOI":"10.1136\/bmj.i3283","volume":"353","author":"A Matthews","year":"2016","unstructured":"Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.","journal-title":"BMJ"},{"key":"6794_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2016","unstructured":"Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37:908\u201316.","journal-title":"Eur Heart J"},{"key":"6794_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5694\/mja15.00103","volume":"202","author":"AL Schaffer","year":"2015","unstructured":"Schaffer AL, Buckley NA, Dobbins TA, Banks E, Pearson SA. The crux of the matter: did the ABC\u2019s catalyst program change statin use in Australia? Med J Aust. 2015;202:591\u20135.","journal-title":"Med J Aust"},{"key":"6794_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMp1006189","volume":"363","author":"NK Choudhry","year":"2010","unstructured":"Choudhry NK, Shrank WH. Four-dollar generics\u2014increased accessibility, impaired quality assurance. N Engl J Med. 2010;363:1885\u20137.","journal-title":"N Engl J Med"},{"key":"6794_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1071\/AH12009","volume":"38","author":"SJ Mansfield","year":"2014","unstructured":"Mansfield SJ. Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England. Aust Health Rev. 2014;38:6\u201315.","journal-title":"Aust Health Rev"},{"key":"6794_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imj.12633","volume":"45","author":"D Gnjidic","year":"2015","unstructured":"Gnjidic D, Wilson N, March L, Cumming RG, Cameron ID, Hilmer SN. Statin utilisation patterns in older Australians living in residential care: 1-year prevalence study. Intern Med J. 2015;45:106\u20139.","journal-title":"Intern Med J"},{"key":"6794_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/pds.3526","volume":"22","author":"JR Warren","year":"2013","unstructured":"Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf. 2013;22:1298\u2013307.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6794_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23937\/2378-2951\/1410016","volume":"1","author":"S Gadzhanova","year":"2014","unstructured":"Gadzhanova S, Roughead E, Ilomaki J. Use of statins in an Australian elderly population. Int J Clin Cardiol. 2014;1:1\u20134.","journal-title":"Int J Clin Cardiol"},{"key":"6794_CR16","unstructured":"Department of Health. About the PBS. 2016."},{"key":"6794_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","volume":"8","author":"L Mellish","year":"2015","unstructured":"Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8:634.","journal-title":"BMC Res Notes"},{"key":"6794_CR18","first-page":"319","volume":"40","author":"LA Simons","year":"2011","unstructured":"Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy\u2014experience in Australia 2006\u20132010. Aust Fam Physician. 2011;40:319\u201322.","journal-title":"Aust Fam Physician"},{"key":"6794_CR19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/j.1326-5377.2008.tb01589.x","volume":"188","author":"LA Simons","year":"2008","unstructured":"Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004\u20132006. Med J Aust. 2008;188:224\u20137.","journal-title":"Med J Aust"},{"key":"6794_CR20","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment Oslo; 2016."},{"key":"6794_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/CVM-2-5-205","volume":"2","author":"CD Furberg","year":"2001","unstructured":"Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205\u20137.","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"6794_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2165\/11537330-000000000-00000","volume":"27","author":"M Geleedst-De Vooght","year":"2010","unstructured":"Geleedst-De Vooght M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010;27:589\u201396.","journal-title":"Drugs Aging"},{"key":"6794_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2125.2008.03258.x","volume":"66","author":"P Ruokoniemi","year":"2008","unstructured":"Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen PJ, Huupponen R. Shift of statin use towards the elderly in 1995\u20132005: a nation-wide register study in Finland. Br J Clin Pharmacol. 2008;66:405\u201310.","journal-title":"Br J Clin Pharmacol"},{"key":"6794_CR24","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"6794_CR25","unstructured":"AIHW. Australia\u2019s changing age and gender profile. 2016."},{"key":"6794_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5694\/mja11.10698","volume":"196","author":"TK Morgan","year":"2012","unstructured":"Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196:50\u20133.","journal-title":"Med J Aust"},{"key":"6794_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","volume":"2","author":"JA Salami","year":"2017","unstructured":"Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017;2:56\u201365.","journal-title":"JAMA Cardiol"},{"key":"6794_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.archger.2015.10.007","volume":"62","author":"SW Narayan","year":"2016","unstructured":"Narayan SW, Tordoff JM, Nishtala PS. Temporal trends in the utilisation of preventive medicines by older people: a 9-year population-based study. Arch Gerontol Geriatr. 2016;62:103\u201311.","journal-title":"Arch Gerontol Geriatr"},{"key":"6794_CR29","doi-asserted-by":"publisher","first-page":"e0158608","DOI":"10.1371\/journal.pone.0158608","volume":"11","author":"LV Minard","year":"2016","unstructured":"Minard LV, Corkum A, Sketris I, Fisher J, Zhang Y, Saleh A. Trends in statin use in seniors 1999 to 2013: time series analysis. PLoS One. 2016;11:e0158608.","journal-title":"PLoS One"},{"key":"6794_CR30","doi-asserted-by":"publisher","first-page":"e010500","DOI":"10.1136\/bmjopen-2015-010500","volume":"6","author":"F Vancheri","year":"2016","unstructured":"Vancheri F, Backlund L, Strender LE, Godman B, Wettermark B. Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open. 2016;6:e010500.","journal-title":"BMJ Open"},{"key":"6794_CR31","doi-asserted-by":"publisher","first-page":"e014150","DOI":"10.1136\/bmjopen-2016-014150","volume":"7","author":"HC Hsieh","year":"2017","unstructured":"Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan\u2019s National Health Insurance Research Database. BMJ Open. 2017;7:e014150.","journal-title":"BMJ Open"},{"key":"6794_CR32","doi-asserted-by":"publisher","first-page":"e003811","DOI":"10.1161\/CIRCOUTCOMES.117.003811","volume":"10","author":"MB Mortensen","year":"2017","unstructured":"Mortensen MB, Falk E, Schmidt M. Twenty-year nationwide trends in statin utilization and expenditure in Denmark. Circ Cardiovasc Qual Outcomes. 2017;10:e003811.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"6794_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/CLEP.S104258","volume":"8","author":"AG O'Keeffe","year":"2016","unstructured":"O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clin Epidemiol. 2016;8:123\u201332.","journal-title":"Clin Epidemiol"},{"key":"6794_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/1755-5922.12236","volume":"35","author":"SA Hollingworth","year":"2017","unstructured":"Hollingworth SA, Ostino R, David MC, Martin JH, Tett SE. Ezetimibe: use, costs, and adverse events in Australia. Cardiovasc Ther. 2017;35:40\u20136.","journal-title":"Cardiovasc Ther"},{"key":"6794_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijcard.2015.07.095","volume":"201","author":"C Kocas","year":"2015","unstructured":"Kocas C, Abaci O, Kocas BB, Cetinkal G, Arslan S, Yildiz A, et al. The role of media on statin adherence. Int J Cardiol. 2015;201:139.","journal-title":"Int J Cardiol"},{"key":"6794_CR36","doi-asserted-by":"publisher","first-page":"e0155228","DOI":"10.1371\/journal.pone.0155228","volume":"11","author":"H Zhang","year":"2016","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study. PLoS One. 2016;11:e0155228.","journal-title":"PLoS One"},{"key":"6794_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40266-012-0032-1","volume":"29","author":"S Bhattacharjee","year":"2012","unstructured":"Bhattacharjee S, Findley PA, Sambamoorthi U. Understanding gender differences in statin use among elderly Medicare beneficiaries: an application of decomposition technique. Drugs Aging. 2012;29:971\u201380.","journal-title":"Drugs Aging"},{"key":"6794_CR38","first-page":"406","volume":"77","author":"P Miller","year":"2016","unstructured":"Miller P. Women and cardiovascular disease: what can health care providers do to reduce the risks? N C Med J. 2016;77:406\u20139.","journal-title":"N C Med J"},{"key":"6794_CR39","first-page":"47","volume":"25","author":"C Vlassoff","year":"2007","unstructured":"Vlassoff C. Gender differences in determinants and consequences of health and illness. J Health Popul Nutr. 2007;25:47\u201361.","journal-title":"J Health Popul Nutr"},{"key":"6794_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10:833\u201341.","journal-title":"J Clin Lipidol"},{"key":"6794_CR41","doi-asserted-by":"crossref","unstructured":"Ofori-Asenso R, Jakhu A, Curtis AJ, Zomer E, Gambhir M, Jaana Korhonen M, et al. A systematic review and meta-analysis of the factors associated with nonadherence and discontinuation of statins among people aged >\/=65 years. J Gerontol A Biol Sci Med Sci. 2018;","DOI":"10.1093\/gerona\/glx256"},{"key":"6794_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/VHRM.S2048","volume":"4","author":"C Escobar","year":"2008","unstructured":"Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag. 2008;4:525\u201333.","journal-title":"Vasc Health Risk Manag"},{"key":"6794_CR43","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425\u201335.","journal-title":"N Engl J Med"},{"key":"6794_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/clc.22338","volume":"38","author":"KA Wilmot","year":"2015","unstructured":"Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: a patient-focused approach. Clin Cardiol. 2015;38:56\u201361.","journal-title":"Clin Cardiol"},{"key":"6794_CR45","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1023\/A:1015828811865","volume":"9","author":"H Cheng","year":"1992","unstructured":"Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res. 1992;9:1629\u201333.","journal-title":"Pharm Res"},{"key":"6794_CR46","unstructured":"Therapeutic Goods Administration. Risk factors for myopathy and rhabdomyolysis with the statins. 2004."},{"key":"6794_CR47","doi-asserted-by":"crossref","unstructured":"Ofori-Asenso R, Jahku A, Zomer E, Curtis A, Korhonen M, Nelson M, et al. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. 2017.","DOI":"10.1093\/gerona\/glx169"},{"key":"6794_CR48","doi-asserted-by":"publisher","first-page":"e102146","DOI":"10.1371\/journal.pone.0102146","volume":"9","author":"C Ferrajolo","year":"2014","unstructured":"Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, Sportiello L, Ferrara R, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One. 2014;9:e102146.","journal-title":"PLoS One"},{"key":"6794_CR49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5694\/j.1326-5377.2010.tb03661.x","volume":"192","author":"PM Clarke","year":"2010","unstructured":"Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust. 2010;192:633\u20136.","journal-title":"Med J Aust"},{"key":"6794_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/14737167.2016.1136790","volume":"16","author":"LP Thai","year":"2016","unstructured":"Thai LP, Moss JR, Godman B, Vitry AI. Cost driver analysis of statin expenditure on Australia\u2019s Pharmaceutical Benefits Scheme. Exp Rev Pharmacoecon Outcomes Res. 2016;16:419\u201333.","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"key":"6794_CR51","first-page":"e495","volume":"63","author":"F Brown","year":"2017","unstructured":"Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician. 2017;63:e495\u2013503.","journal-title":"Can Fam Physician"},{"key":"6794_CR52","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1371\/journal.pmed.0020123","volume":"2","author":"J Ma","year":"2005","unstructured":"Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2:e123.","journal-title":"PLoS Med"},{"key":"6794_CR53","doi-asserted-by":"publisher","first-page":"e003626","DOI":"10.1161\/CIRCOUTCOMES.117.003626","volume":"10","author":"JN Booth 3rd","year":"2017","unstructured":"Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, et al. Statin discontinuation, reinitiation, and persistence patterns among Medicare beneficiaries after myocardial infarction: a cohort study. Circ Cardiovasc Qual Outcomes. 2017;10:e003626.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6794-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T06:07:37Z","timestamp":1571378857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6794-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6794"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6794-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"23 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RO declares no that he has no conflict of interest. JI declares that she has no conflict of interest. EZ declares that she has no conflict of interest. AC declares that she has no conflict of interest. SZ reports past participation in advisory boards and\/or receiving honoraria from AstraZeneca\/Bristol-Myers Squibb Australia; Janssen-Cilag; Merck, Sharp, and Dohme (Australia); Novartis Australia; Novo Nordisk; Sanofi and Servier Laboratories for work unrelated to this study. DL reports past participation in advisory boards and\/or receiving honoraria from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi and Shire for work unrelated to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study received ethics approval from Monash University Human Research Ethics Committee (approval number 5871). No direct human participants were involved. The Australian Government Department of Human Services also approved the analysis plan and the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}